Could the Cost of Cancer Immunotherapy Overshadow Its Effectiveness?

One important issue concerning immunotherapy, which has become an indispensable part of cancer treatment despite having a history of only a few years, is its cost. The costs of treatments involving these drugs intimidate even the wealthiest countries. As physicians, while we are excited that these drugs produce significant survival differences in various cancers, we are also concerned about how feasible their use in clinical practice will be because of their extremely high cost.
One of the topics at the Best of ASCO 2015 Istanbul meeting, which began today, was barriers to accessing new treatments in oncology. During the discussion, we observed that our colleagues attending from abroad shared similar concerns about immunotherapy costs.
For example, in the squamous cell subtype of lung cancer, a drug (nivolumab) produced a survival difference of more than 3 months for the first time in many years, but treating even a single patient with these drugs costs hundreds of thousands of lira. Moreover, these new-generation immunotherapy drugs do not yet promise a cure (complete recovery from the disease), but only prolong survival. Although we wholeheartedly believe and advocate that every patient deserves the best treatment, will we be able to afford these treatments for a cancer with as many patients as lung cancer?
When pharmaceutical companies are asked why new drugs are so expensive, the very high cost of drug development is the standard response. Although this answer has some justification, is it true that when pharmaceutical companies recognize that a new drug they have developed is effective and that choosing these drugs is inevitable, they market them at prices far above their production costs?
The Greatest Barrier to Accessing New Treatments: Cost!
One of the discussion subtopics was the question, can the cost barrier be overcome ? Countries acting together to negotiate more firmly with pharmaceutical companies, producing our own biosimilar drugs, and ensuring participation in more clinical trials were some of the proposed solutions...
Overcoming the barriers to our patients' access to the best treatments does not depend solely on the responsibility, common sense, and problem-solving abilities of governments, drug developers, and physicians; perhaps it depends most on increased public awareness. For this reason, in our articles this week, we have tried to explain many aspects of cancer immunotherapy, a subject we will hear about and discuss frequently in the coming period.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.